Cargando…
Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis
Observational studies have suggested that HER2 inhibition with trastuzumab may be associated with an increased incidence of intracranial metastatic disease (IMD) due to its ability to prolong survival. We hypothesized that prolonged survival associated with dual-agent HER2 inhibition may be associat...
Autores principales: | Erickson, Anders Wilder, Habbous, Steven, Hoey, Christianne, Jerzak, Katarzyna J., Das, Sunit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892568/ https://www.ncbi.nlm.nih.gov/pubmed/33602948 http://dx.doi.org/10.1038/s41523-021-00220-0 |
Ejemplares similares
-
HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis
por: Erickson, Anders W, et al.
Publicado: (2020) -
THER-01. Targeted therapy and intracranial metastatic disease: a population-based retrospective cohort study
por: Erickson, Anders, et al.
Publicado: (2021) -
The Impact of Targeted Therapy on Intracranial Metastatic Disease Incidence and Survival
por: Erickson, Anders W., et al.
Publicado: (2019) -
Incidence and real-world burden of brain metastases from solid tumors and hematologic malignancies in Ontario: a population-based study
por: Habbous, Steven, et al.
Publicado: (2020) -
Intracranial Metastatic Disease: Present Challenges, Future Opportunities
por: Li, Alyssa Y., et al.
Publicado: (2022)